Evidence map›Paper›PMID 35480124›Full record

ArticleFrontiers in oncology2022

Mucinous Tubular and Spindle Cell Carcinoma of the Kidney: A Study of Clinical, Imaging Features and Treatment Outcomes.

Xiaofeng Xu, Jing Zhong, Xiumin Zhou, Zhifeng Wei, Qiuyuan Xia, Pengfei Huang, Changjie Shi, Jianping Da, Chaopeng Tang, Wen Cheng and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Role ofJapanese journal of radiology · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. [Mucinous tubular and spindle cell carcinoma of kidney: Clinicopathology and prognosis].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2023
    Article
  11. A case report of mucinous tubular and spindle cell carcinoma of the kidney.American journal of clinical and experimental urology · 2023
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Xiaofeng XuDepartment of Urology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China.
Jing ZhongDepartment of Radiology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China.
Xiumin ZhouDepartment of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Zhifeng WeiDepartment of Urology, The Fourth Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Qiuyuan XiaDepartment of Pathology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China.
Pengfei HuangDepartment of Ultrasound Diagnosis, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China.
Changjie ShiDepartment of Urology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China.
Jianping DaDepartment of Urology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China.
Chaopeng TangDepartment of Urology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China.
Wen ChengDepartment of Urology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China.
Jingping GeDepartment of Urology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China.
Nanjing University · CNNanjing General Hospital of Nanjing Military Command · CNFirst Affiliated Hospital of Soochow University · CNSecond Affiliated Hospital of Nanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To describe the clinical, imaging, pathological features and oncologic outcomes of mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney. Patients and Methods: Twenty-two cases of MTSCC were pathologically identified between January 2004 and April 2021 at our institution. The clinical and imaging findings, pathological features, treatment methods and outcomes of the patients were reviewed. Results: These cases included 17 women and 5 men, with a median age at diagnosis of 52.5 years. On contrast-enhanced CT, MTSCC was less enhanced than the adjacent renal parenchyma. Tumor attenuation values were 33.3 ± 6.8HU, 44.0 ± 9.1HU, 54.4 ± 13.9HU and 67.1 ± 11.8HU in the non-contrast, corticomedullary, nephrographic and excretory phases of CT, respectively. Contrast-enhanced ultrasonography and MRI also showed hypovascular features of the masses. On MRI, the tumors were isointense on T1-weighted images and slightly hypo- or hyperintense on T2-weighted images. Diffusion-weighted imaging revealed a low apparent diffusion coefficient of the tumor. The patients were managed with laparoscopic partial nephrectomy (n=5), radical nephrectomy (n=16), or robotic-assisted laparoscopic partial nephrectomy (n=1). The median follow-up time was 59.5 months. All the patients were free of local recurrence or distant metastasis. Conclusions: MTSCC is generally indolent and has favorable outcomes. The imaging features of MTSCC are generally hypovascular, which is significantly different from clear cell renal cell carcinoma. However, it is still difficult to distinguish MTSCC from other hypovascular renal tumors preoperatively because their imaging features overlap. Further studies are essential to fully characterize the features of this rare RCC variant.

Indexed as

imaging featureskidneymucinous tubular and spindle cell carcinomaprognosisrenal cell carcinoma

Identifiers

PMID35480124
PMCPMC9035933
OpenAlexW4223599771

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.